Lausanne – July 25, 2017 – Galderma announced today the enrollment of the first patient in a multicenter double-blind Phase IIb clinical trial to evaluate nemolizumab, its investigational subcutaneous anti-IL-31 receptor A (RA) monoclonal antibody, in patients with atopic dermatitis (AD).

Rewarding Patient Loyalty through Value Incentive Offer on Restylane® Treatments from Aesthetic Professionals

• Launching in May, an inaugural four-part webinar series Unmasking Facial Skin & Dermatoses will feature expert presentations from world-renowned dermatologists
• The program launches the Galderma Excellence in Multichannel Medical Education (GEMME) platform, demonstrating its commitment to innovative and science-led approaches in skin health

• New Nemluvio® (nemolizumab) post-hoc data from the ARCADIA long-term extension (LTE) study showed the majority of Week 16 responders maintained deep and lasting skin lesion and itch response for up to three years¹
• Additional long-term data further demonstrate Nemluvio’s consistent safety profile and sustained efficacy, including improvements in s

• Business-building webinars to support local Aesthetic practices
• Expert injector techniques by GAIN faculty

Lausanne, Switzerland, April 15, Galderma is continuing its commitment to education and training in aesthetics by leveraging the most advanced digital technologies to help customers navigate through the challenges induced by the COVID-19 pan